US prescriptions of CARBATROL for the six months ending June 30, 2007 were down 5% compared to the same period in 2006. This was primarily due to a comparable decline in the US extended release carbamazepine prescription market.
Sales of CARBATROL for the six months to June 30, 2007 were $33.4 million, an increase of 10% compared to the same period in 2006 (2006: $30.3 million). Although there was a decrease in US prescriptions, sales rose due to price increases in July 2006 and April 2007.
Sales for the six months to June 30, 2007 were $31.6 million, an increase of 21% compared to the same period in 2006 (2006: $26.2 million). Expressed in transaction currencies (XAGRID is primarily sold in Euros), sales increased by 11% due to growth in many of Shire's markets. In addition there was a 10% benefit from favorable exchange rate movements against the US dollar.
Sales for the six months to June 30, 2007 were $64.4 million (2006: $54.1 million). This increase of 19% is primarily due to higher unit sales in Europe and Canada, with 8% accounted by the impact of favorable exchange rates.
ELAPRASE was launched in the US in August 2006 and in Canada and several major European markets during the first half of 2007. ELAPRASE is now sold in 25 countries. Sales for the six months to June 30, 2007 were $69.3 million.
Foreign exchange effect
As many of Shire's sales revenues are denominated in currencies other
than US dollars (primarily Canadian dollars, Euros and Pounds sterling),
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved